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concentration of the metabolite in the cancer group (p = 0.040). 
Subsequently, EBC samples were analyzed by an LC-QTOF-Mass 
Spectroscopy (MS) using a non-targeted approach. A total of 625 
compounds were detected in all EBC samples combined among 
which, four were up regulated in patients with lung cancer (T-
Test, p < 0.05). 
Conclusions: Lower concentrations of methanol (EBC), 
glycoprotein (sputum), absence of glucose in sputum identified 
through MRS and up regulation of four specific metabolites in EBC 
identified through MS in patients with known lung cancer suggest 
that MRS and MS may provide a lung cancer specific metabolic 
profile that can be used to develop a non-invasive tool to screen 
for lung cancer in high-risk population. 
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Purpose: Non-small cell lung cancer (NSCLC) frequently 
progresses during the interval between diagnosis and initiation 
of radiation therapy. We have previously demonstrated that 
tumour growth rate (GR) is an important predictor of local-
regional control and survival in early lung cancer patients treated 
with SBRT using specific growth rate (SGR) as a metric for tumour 
growth rate, and its median (0.43x10-2) as a cut off to group 
patients into high and low SGR groups. The aim of this study was 
to:  
1) validate SGR value of 0.43x10-2 as a metric for GR; and 2)
determine the influence of pre-treatment tumour SGR on 
outcomes of early stage NSCLC patients treated with SBRT at a 
second institution. 
Methods and Materials: A retrospective chart review of 160 
patients with pathologically confirmed T1-2 N0 NSCLC patients 
treated with SBRT between June 2010 and December 2012 was 
undertaken. Demographic and clinical data were collected from 
an institutional database. Time between diagnostic and 
simulation CT scans was calculated (t). Diagnostic CT was 
uploaded to Focal planning software v.4.70. Gross tumour was 
contoured on each slice using lung window to calculate Gross 
Tumour Volume (GTV1). The pre-treatment planning CT images 
were uploaded from archived files to record the pre-treatment 
GTV (GTV2). SGR was calculated using the equation: SGR = ln 
(GTV2/GTV1)/t). The SGR cut offv(0.43x10-2) from our previous 
data was used to group patients into two cohorts. Kaplan-Meier 
curves were constructed for both overall (OS) and failure-free 
survivals (FFS), and the log rank for comparison between high 
and low SGR groups. Multivariate analyses were performed using 
a Cox proportional hazard model with SGR and other relevant 
clinical factors. 
Results: Median time interval between initial diagnostic and 
planning CT scans was 87 days (range: 5-338). The median SGR 
was 0.418 x 10-2 (range -1.1x10-2; -5.1910-2). Median GTV1 was 
3.5 cm3 (range: 0.2; 51.9 cm3) and median GTV2 was 6 cm3 
(range: 0.2; 79.1 cm3). At median follow up period of 35.8 
months, the median OS was 54 months. Three years OS was 60%. 
Patients were grouped into high and low SGR using previously 
reported SGR median as a cut off (0.43x10-2). The median 
survival was 30.3 months for high SGR versus 44.6 months for low 
SGR (p = 0.02). The median FFS was 36 months for high SGR 
versus 51.9 months for low SGR groups respectively (p < 0.01). 
On univariable analysis, gender (p = < 0.01), Stage T2 (p < 0.01), 
and GTV2 (p < 0.01) were also predictive for OS and FFS. On 
multivariate analysis only male gender (p = 0.006) and GTV2 (p = 
0.04) were predictive for OS and high SGR (p = 0.01), male gender 
(p = < 0.01), and GTV2 (p = < 0.01) were independent predictors 
for poorer FFS. 
Conclusions: This analysis of an independent data set confirmed 
the validity of pre-treatment SGR. High SGR was associated with 
poorer outcome in patients with early stage NSCLC treated with 
SBRT. Further work to correlate and combine its use with 
biological markers is ongoing. 
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Purpose: The prognostic and predictive value of 18F-FDG PET 
scans performed midway through curative-intent 
chemoradiotherapy for non-small cell lung cancer (NSCLC) 
remains to be established. This study aimed to determine if mid-
treatment 18F-FDG PET parameters predicted for the outcome 
of these patients. 
Methods and Materials: Between 2008 and 2012, nine 
consecutive patients with histologically-proven, unresected 
NSCLC who were fit to undergo curative-intent 
chemoradiotherapy (CRT) were prospectively accrued for study. 
18F-FDG PET scans were performed at baseline and after 20 
fractions of CRT. Mean standardized uptake value (SUVmean), 
maximum SUV (SUVmax) and metabolic tumour volume (MTV) 
were obtained. MTVs were automatically delineated at 50% of 
SUVmax for each lesion using a dedicated software package. 
Total lesion glycolysis (TLG) was calculated as mean SUV x MTV 
(cm3). Changes in TLG (Δ TLG) and SUVmax (Δ SUVmax) from 
baseline were used to quantify early metabolic tumour 
responses. Patients were followed for a median of 16 months 
(range 5.4 – 57.1 months). Repeat FDG-PET scan scans were 
performed at one, three, and 12 months following treatment or 
if patients had symptoms suggestive of locoregional progression 
or recurrence. Overall survival (OS) and progression-free survival 
(PFS) were calculated using the Kaplan-Meier method. Log-rank 
tests were used to compare the two survival curves. 
Results: Seven patients had AJCC Stage IIIa and two patients had 
Stage IIIb NSCLC. At the time of last follow up, three patients 
were alive and without recurrent disease. A reduction in TLG (Δ 
TLG) by 75% or more was associated with longer OS (12.5 versus 
16.4 months, p = 0.048). Baseline TLG values of 414.8 or less 
were associated with longer PFS (7.2 versus 9.0 months, p = 
0.048). Baseline and Δ SUVmax values were not associated with 
OS or PFS. 
Conclusions:  Early metabolic response midway through 
radiotherapy as quantified by Δ TLG by 75% or more was 
associated with longer OS. SUVmax at baseline and mid-
treatment and Δ SUVmax were not associated with OS or PFS. 
Early identification of poor CRT responders may allow for future 
clinical trials to improve outcomes in these patients, such as dose 
escalation with an additional RT boost. Larger studies are needed 
to confirm these findings 
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Purpose: Stereotactic ablative radiotherapy (SABR) is an 
effective treatment for patients with peripherally-located early-
stage non-small cell lung cancer (ES-NSCLC). Treatment-related 
toxicity for SABR is uncommon, with a Grade 5 toxicity rate of 
0.4% in medically operable patients [Onishi et al. 2015]. Growing 
evidence suggests that patients with interstitial lung disease 
